Cardialen, a Minnesota-based healthcare technology company, has received a $3 million grant from the National Institutes of Health to continue developing a new low-energy therapy for atrial fibrillation (AFib).
A panel of cardiologists, scientists and engineering specialists reviewed early data on Cardialen’s MultiPulse Therapy (MPT), which is designed to help patients who are already scheduled to receive an implantable cardiac resynchronization therapy defibrillator (CRT-D) device. AFib, the company noted, is quite common among patients with such devices.
Prash Sanders, MDDS, PhD, a cardiologist at Adelaide Medical School in Australia, led a clinical trial focused on MPT.
“AFib remains a serious arrhythmia, and additional treatment options are needed,” Sanders said in a prepared statement. “Maintaining AFib rhythm control in heart failure patients has shown to provide significant quality of life, mortality and hospitalization benefits. Cardialen’s MultiPulse Therapy could provide another important tool for patients receiving a CRT-D device.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.